Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation

World Journal of Gastroenterology

Volumn 19, Issue 48, 2013, Pages 9189-9197

  Cholongitas, Evangelos ^a   Papatheodoridis, George V ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adefovir; Antivirals; Entecavir; Hepatitis B virus; Hepatitis B virus immunoglobulin; Lamivudine; Liver transplantation; Resistance; Telbivudine; Tenofovir

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; BILIRUBIN; CALCINEURIN INHIBITOR; CREATININE; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; NUCLEOTIDE ANALOGUE; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEPATITIS B; HUMAN; INCIDENCE; KIDNEY DISEASE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; OUTCOME ASSESSMENT; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SCORING SYSTEM; SYSTEMATIC REVIEW (TOPIC); VIRUS REPLICATION;

ADEFOVIR; ANTIVIRALS; ENTECAVIR; HEPATITIS B VIRUS; HEPATITIS B VIRUS IMMUNOGLOBULIN; LAMIVUDINE; LIVER TRANSPLANTATION; RESISTANCE; TELBIVUDINE; TENOFOVIR;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS B; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84891421019     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i48.9189     Document Type: Article

References (79)

1. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000; 61: 362-366 [PMID:10861647]
2. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012; 57: 442-450 [PMID: 22504333 DOI: 10.1016/ j.jhep.2012.02.033]
3. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8: 167-178 [PMID: 18053766 DOI: 10.1016/ S1473-3099(07)70264-5]
4. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847 [PMID: 8247035 DOI: 10.1056/ NEJM199312163292503]
5. Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009; 29: 1294-1305 [PMID: 19619264 DOI: 10.1111/j.1478-3231.2009.02085.x]
6. Papatheodoridis GV, Sevastianos V, Burroughs AK. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant 2003; 3: 250-258 [PMID: 12614278 DOI: 10.1034/ j.1600-6143.2003.00063.x]
7. Papatheodoridis GV. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues? Liver Int 2013; 33 Suppl 1: 151-156 [PMID: 23286859 DOI:10.1111/liv.12054]
8. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/ hep.23190]
9. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
10. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531 [PMID: 15470215 DOI: 10.1056/NEJMoa033364]
11. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-210 [PMID: 10613747]
12. Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul R, Agarwal SR, Raisuddin S, Hasnain SE, Sarin SK. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33: 308-312 [PMID: 10952249 DOI:10.1016/S0168-8278(00)80372-4]
13. Manolakopoulos S, Karatapanis S, Elefsiniotis J, Mathou N, Vlachogiannakos J, Iliadou E, Kougioumtzan A, Economou M, Triantos C, Tzourmakliotis D, Avgerinos A. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004; 99: 57-63 [PMID: 14687142 DOI: 10.1046/j.1572-0241.2003.04021.x]
14. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-1722 [PMID: 14724824 DOI: 10.1053/j.gastro.2003.09.033]
15. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 219-226 [PMID: 12085368 DOI: 10.1053/jhep.2002.33894]
16. Merle P, Trepo C. Therapeutic management of hepatitis B-related cirrhosis. J Viral Hepat 2001; 8: 391-399 [PMID: 11703569 DOI: 10.1046/j.1365-2893.2001.00299.x]
17. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895-902 [PMID: 11451174 DOI: 10.1016/ S0168-8278(01)00089-7]
18. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Busuttil RW. Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B. Transplant Proc 2007; 39: 3276-3280 [PMID: 18089370 DOI: 10.1016/j.transproceed.2007.07.085]
19. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann H, Samuel D, Zeuzem S, Villeneuve JP, Arterburn S, Borroto-Esoda K, Brosgart C, Chuck S. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final longterm results. Liver Transpl 2007; 13: 349-360 [PMID: 17326221 DOI: 10.1002/lt.20981]
20. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807 [PMID: 12606734 DOI:10.1056/NEJMoa021812]
21. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455 [PMID: 19052126 DOI: 10.1056/NEJMoa0802878]
22. Hadziyannis SJ, Papatheodoridis GV. Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. Expert Rev Anti Infect Ther 2004; 2: 475-483 [PMID: 15482214 DOI:10.1586/14787210.2.4.475]
23. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL. Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751 [PMID: 17087951 DOI: 10.1053/ j.gastro.2006.09.020]
24. Gara N, Zhao X, Collins MT, Chong WH, Kleiner DE, Jake Liang T, Ghany MG, Hoofnagle JH. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 2012; 35: 1317-1325 [PMID: 22506503 DOI: 10.1111/j.1365-2036.2012.05093.x]
25. Ha NB, Ha NB, Garcia RT, Trinh HN, Vu AA, Nguyen HA, Nguyen KK, Levitt BS, Nguyen MH. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009; 50: 727-734 [PMID: 19517525 DOI: 10.1002/ hep.23044]
26. Izzedine H, Hulot JS, Launay-Vacher V, Marcellini P, Hadziyannis SJ, Currie G, Brosgart CL, Westland C, Arterbrun S, Deray G. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebocontrolled studies. Kidney Int 2004; 66: 1153-1158 [PMID: 15327411 DOI: 10.1111/j.1523-1755.2004.00866.x]
27. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588 [PMID: 18094378 DOI: 10.1056/NEJMoa066422]
28. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495 [PMID: 19027013 DOI: 10.1053/j.gastro.2008.10.026]
29. Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, Hwang SG, Choudhuri G, Safadi R, Tanwandee T, Chutaputti A, Yurdaydin C, Bao W, Avila C, Trylesinski A. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012; 19: 732-743 [PMID: 22967105 DOI: 10.1111/ j.1365-2893.2012.01600.x]
30. Pipili CL, Papatheodoridis GV, Cholongitas EC. Treatment of hepatitis B in patients with chronic kidney disease. Kidney Int 2013; 84: 880-885 [PMID: 23783238 DOI: 10.1038/ ki.2013.249]
31. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176-182 [PMID: 20006394 DOI: 10.1016/ j.jhep.2009.11.007]
32. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893 [PMID: 20683932 DOI: 10.1002/ hep.23785]
33. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514 [PMID: 19280622 DOI: 10.1002/hep.22841]
34. Schiff E, Simsek H, Lee WM, Chao YC, Sette H, Janssen HL, Han SH, Goodman Z, Yang J, Brett-Smith H, Tamez R. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008; 103: 2776-2783 [PMID: 18721244 DOI:10.1111/j.1572-0241.2008.02086.x]
35. Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, Sarrazin C. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-2006 [PMID: 19937695 DOI: 10.1002/hep.23346]
36. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242 [PMID: 19054588 DOI:10.1016/j.jhep.2008.10.001]
37. Tenney DJ, Pokornowski KA, Rose RE, Baldick CJ, Eggers BJ, Fang J, Yang JY, Xu D, Brett-Smith H, Spiegelmacher N, Schwendel A, Pichl T, Reeb I, Colonno RJ. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Z Gastroenterol 2008; 46: P059 [DOI: 10.1055/s-0028-1089435]
38. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006; 26: 162-170 [PMID: 16673294 DOI: 10.1055/ s-2006-939758]
39. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. Threeyear efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-143 [PMID: 20955704 DOI: 10.1053/j.gastro.2010.10.011]
40. Karatayli E, Idilman R, Karatayli SC, Cevik E, Yakut M, Seven G, Kabaçam G, Bozdayi AM, Yurdaydin C. Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir. Antivir Ther 2013; 18: 77-85 [PMID: 22878399 DOI: 10.3851/IMP2294]
41. Kim YJ, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. World J Gastroenterol 2012; 18: 6996-7002 [PMID: 23322999 DOI: 10.3748/ wjg.v18.i47.6996]
42. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, Kitrinos K, Svarovskaia ES, Miller MD, Sorbel J, Heathcote J, Marcellin P, Borroto-Esoda K. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011; 53: 763-773 [PMID: 21374657 DOI:10.1002/hep.24078]
43. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-475 [PMID: 23234725 DOI: 10.1016/S0140-6736(12)61425-1]
44. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, Horban A, Wang C, Kwan P, Buti M, Prieto M, Berg T, Kitrinos K, Peschell K, Mondou E, Frederick D, Rousseau F, Schiff ER. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72 [PMID: 21254162 DOI: 10.1002/ hep.23952]
45. Murray KF, Carithers RL. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-1432 [PMID: 15880505 DOI: 10.1002/hep.20704]
46. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539 [PMID: 17256718 DOI: 10.1002/hep.21513]
47. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-727 [PMID: 12198698 DOI:10.1053/gast.2002.35352]
48. Zoulim F, Radenne S, Ducerf C. Management of patients with decompensated hepatitis B virus associated [corrected] cirrhosis. Liver Transpl 2008; 14 Suppl 2: S1-S7 [PMID: 18825719 DOI: 10.1002/lt.21615]
49. Hyun JJ, Seo YS, Yoon E, Kim TH, Kim DJ, Kang HS, Jung ES, Kim JH, An H, Kim JH, Yim HJ, Yeon JE, Lee HS, Byun KS, Um SH, Kim CD, Ryu HS. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. Liver Int 2012; 32: 656-664 [PMID: 22099071 DOI: 10.1111/ j.1478-3231.2011.02676.x]
50. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 1189-1195 [PMID: 11093723 DOI: 10.1053/jhep.2000.19789]
51. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, Caldwell SH, Pruett TL. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358-1364 [PMID: 8629297 DOI: 10.1097/00007890-199605150-00013]
52. Sawyer RG, McGory RW, Gaffey MJ, McCullough CC, Shephard BL, Houlgrave CW, Ryan TS, Kuhns M, McNamara A, Caldwell SH, Abdulkareem A, Pruett TL. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998; 227: 841-850 [PMID: 9637547 DOI: 10.1097/00 000658-199806000-00007]
53. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, Ascher NL, Wright TL. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327-1333 [PMID: 8938155 DOI: 10.1002/hep.510240601]
54. Fox AN, Terrault NA. The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol 2012; 56: 1189-1197 [PMID: 22274310 DOI: 10.1016/j.jhep.2011.08.026]
55. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transpl 2011; 17: 1176-1190 [PMID: 21656655 DOI: 10.1002/lt.22354]
56. Hooman N, Rifai K, Hadem J, Vaske B, Philipp G, Priess A, Klempnauer J, Tillmann HL, Manns MP, Rosenau J. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl 2008; 14: 435-442 [PMID: 18383078 DOI: 10.1002/lt.21343]
57. Powell JJ, Apiratpracha W, Partovi N, Erb SR, Scudamore CH, Steinbrecher UP, Buczkowski AK, Chung SW, Yoshida EM. Subcutaneous administration of hepatitis B immune globulin in combination with lamivudine following orthotopic liver transplantation: effective prophylaxis against recurrence. Clin Transplant 2006; 20: 524-525 [PMID: 16842532 DOI: 10.1111/j.1399-0012.2006.00517.x]
58. Chaib E, Coimbra BG, Galvão FH, Tatebe ER, Shinzato MS, D'Albuquerque LA, Massad E. Does anti-hepatitis B virus vaccine make any difference in long-term number of liver transplantation? Clin Transplant 2012; 26: E590-E595 [PMID: 23083337 DOI: 10.1111/ctr.12030]
59. Tahara H, Tanaka Y, Ishiyama K, Ide K, Shishida M, Irei T, Ushitora Y, Ohira M, Banshodani M, Tashiro H, Itamoto T, Asahara T, Imamura M, Takahashi S, Chayama K, Ohdan H. Successful hepatitis B vaccination in liver transplant recipients with donor-specific hyporesponsiveness. Transpl Int 2009; 22: 805-813 [PMID: 19490542 DOI: 10.1111/ j.1432-2277.2009.00864.x]
60. Lo CM, Liu CL, Chan SC, Lau GK, Fan ST. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 2005; 43: 283-287 [PMID: 15964658 DOI: 10.1016/ j.jhep.2005.03.013]
61. Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, Csako G. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 696-700 [PMID: 18456569 DOI: 10.1016/j.cgh.2008.02.055]
62. Katz LH, Paul M, Guy DG, Tur-Kaspa R. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl Infect Dis 2010; 12: 292-308 [PMID: 20002355 DOI: 10.1111/j.1399-3062.2009.00470.x]
63. Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004; 24 Suppl 1: 55-62 [PMID: 15192802 DOI: 10.1055/s-2004-828679]
64. Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant 2013; 13: 353-362 [PMID: 23137006 DOI: 10.1111/j.1600-6143.2012.04315.x]
65. Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, Herrero JI, Jardí R, Cruz de Castro E, García-Rey C. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38: 811-817 [PMID: 12763375 DOI:10.1016/S0168-8278(03)00087-4]
66. Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, de Man RA, Bassendine M, O'Grady JG, Portmann BC, Anschuetz G, Barrett CA, Williams R, Atkins M. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34: 888-894 [PMID: 11451173 DOI: 10.1016/S0168-8278(01)00039-3]
67. Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, Herrero JI, Jardi R, Esteban R. Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007; 84: 650-654 [PMID: 17876280 DOI: 10.1097/01.tp.0000277289.23677.0a]
68. Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis E. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis 2012; 14: 479-487 [PMID: 22624695 DOI: 10.1111/ j.1399-3062.2012.00741.x]
69. Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G, Burroughs A, Hubscher S, Dhillon AP, Rolles K, Elias E. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000; 70: 809-815 [PMID: 11003363 DOI: 10.1097/0000789 0-200009150-00018]
70. Malkan G, Cattral MS, Humar A, Al Asghar H, Greig PD, Hemming AW, Levy GA, Lilly LB. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation 2000; 69: 1403-1407 [PMID: 10798762 DOI:10.1097/00007890-200004150-00033]
71. Wai CT, Lim SG, Tan KC. Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients in Singapore. Gut 2001; 48: 581 [PMID: 11288740 DOI: 10.1136/ gut.48.4.581]
72. Fontana RJ, Keefe EB, Han S, Wright T, Davis GL, Lilly L, et al. Prevention of recurrent hepatitis B infection following liver transplantation: Experience in 112 North American patients. Hepatology 1999; 30: 301A
73. Chan HL, Chui AK, Lau WY, Chan FK, Hui AY, Rao AR, Wong J, Lai EC, Sung JJ. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. Clin Transplant 2004; 18: 295-300 [PMID: 15142051 DOI: 10.1111/j.1399-0012.2004.00163.x]
74. Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, Zhang M. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006; 12: 253-258 [PMID: 16447195 DOI: 10.1002/lt.20701]
75. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, Dai WC, Chan AC, Cheung TT, Tsang S, Lam B, Lai CL, Lo CM. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141: 1212-1219 [PMID: 21762659 DOI: 10.1053/ j.gastro.2011.06.083]
76. Fung J, Chan SC, Cheung C, Yuen MF, Chok KS, Sharr W, Chan AC, Cheung TT, Seto WK, Fan ST, Lai CL, Lo CM. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol 2013; 108: 942-948 [PMID: 23629601 DOI: 10.1038/ ajg.2013.111]
77. Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, Tzourmakliotis D, Manesis E, Hadziyannis SJ. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121-129 [PMID: 15962291 DOI: 10.1002/hep.20760]
78. Lenci I, Tisone G, Di Paolo D, Marcuccilli F, Tariciotti L, Ciotti M, Svicher V, Perno CF, Angelico M. Safety of complete and sustained prophylaxis withdrawal in patients livertransplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol 2011; 55: 587-593 [PMID: 21251938 DOI:10.1016/j.jhep.2010.12.036]
79. Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010; 52: 272-279 [PMID: 20034693 DOI:10.1016/j.jhep.2009.11.009]